64 results about "Allotransplantation" patented technology

The invention discloses a method for preparing T cells with knockout of double genes TCR and HLA. The method comprises the following steps: co-transfecting T cells by plasmids of CRISPR/Cas9-HLA and CRISPR/CAs9-TCR, and carrying out knockout of double genes TCR and HLA to obtain the T cells with knockout of double genes TCR and HLA. The method can be used for allotransplantation without causing immunological rejection.

Methods of treating autoimmune disorders, coronary artery disease, allergy symptoms, allograft rejection sepsis/toxic shock are disclosed. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3 in combination with a T suppressor stimulus and/or an antigen. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3. Some methods comprise administering soluble GITR or antibodies that bind to GITR ligand. Methods of treating cancer, infectious diseases, and immune deficiency are also disclosed as are vaccination methods. The methods comprise administering one or more regulatory compositions to inactivate the T suppressor cells by reducing the acetylation level and/or protein level of FOXP3. Improved vaccines and vaccination methods are disclosed. Methods of identifying compounds that are useful to modulate acetylation level and/or protein level of FOXP3 and treat diseases are disclosed.

The invention discloses a method for establishing an immunodeficiency mouse model. The method comprises the following steps of: (1) constructing DNA (deoxyribonucleic acid) which enables functions of an immune related gene in a mouse cell to be lost; (2) purifying mRNA (messenger ribonucleic acid), and cryopreserving in a super-purified water of RNAase free; (4) feeding a pregnant female mouse and a pseudopregnant female mouse under an SPF (specific pathogen free) level feeding condition; (5) taking a fallopian tube from the abdominal cavity of the pregnant female mouse in the step (4), and collecting fertilized ovum; (6) injecting the mRNA obtained in the step (3) into the pronucleus of the fertilized ovum in the step (5) by using a microinjection method; (7) transplanting the fertilized ovum obtained in the step (6) into the body of the pseudopregnant female mouse obtained in the step (4), and enabling the pseudopregnant female mouse to culture the second generation; (8) establishing a stable deficient mouse strain. The method has the advantages that a mouse model which completely does not have immunological rejection to allotransplantation can be obtained for testing.

The present invention relates in general to the field of tissue engineering, and in particular to methods for repair and regeneration of diseased and injured bone and cartilage tissue by allotransplantation or xenotransplantation of neonatal mandibular condyle-derived chondrocytes. The composition may comprise mandibular condyle-derived chondrocytes in the form of a chondrocyte film, per se, or in combination with a scaffold.

Methods of prolonging survival of a transplanted organ, as well as methods of preventing or attenuating rejection of a transplanted organ are provided. These methods involve contacting the organ with an inhibitor of complement activity (e.g., a complement inhibitor that has a maximum molecular weight of 70 kDa and/or a half-life shorter than 10 days, such as a CR2-FH fusion protein or a single chain anti-C5 antibody), prior to transplantation The methods also include administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. A pretreatment with an alternative complement inhibitor was found to be effective in improving graft survival and decreasing ischemia-reperfusion injury in animal.

The invention discloses a preparation method of a tissue engineering acellular vascular scaffold. Enhanced tissue engineering blood vessels without immunogenicity can be obtained by embedding micron high-molecular polymer scaffold into subcutaneous part or abdominal cavity of a host and performing acellular treatment on the blood vessel scaffold wrapped by utilizing a host immune protection mechanism. The preparation method has the advantages that deficient mechanical performance of the tissue engineering acellular blood vessel can be solved, and the mechanical performance of the original tissue engineering acellular vascular scaffold can be fully improved through a multilayer cross-linked mesh type high-molecular scaffold; the problem of immunogenicity of the tissue engineering blood vessel in allotransplantation can be solved, the scaffold blood vessel formed by migrating cells caused by immunologic mechanism is established in a host animal body, the transplanted immunoreaction can be reduced through acellular treatment, extracellular matrix is fully utilized to provide a good environment for cell regeneration; and different acellular vascular scaffolds can be prepared through designing scaffolds of different shapes and sizes of by utilizing the method, so as to be applied under different blood vessel transplanting conditions.

The invention discloses a chimeric antigen receptor adipose-derived stem cell and a preparation method thereof. The chimeric antigen receptor adipose-derived stem cell is composed of a chimeric antigen receptor, an adipose-derived stem cell body and a tumor killing factor. The high-targeting characteristic that the antigen receptor is specifically combined with a specific tumor type, the characteristics that a fatty liver cell is low in immunogenicity, prone to be infected with viruses and capable of being amplified in a large scale within a short time and the tumor resisting function of the tumor killing factor are combined, and therefore the problems of immune storms, low chimeric antigen expression efficiency and allotransplantation immunological rejection during existing CART tumor treatment can be solved, and the tumor treating effect is improved. The improved adipose-derived stem cell has the efficient targeting performance of being specifically transferred to a specific tumor position, the risk that an immune system is excessively activated, and consequently immunological rejection is caused is avoided, the tumor killing factor carried by the adipose-derived stem cell can efficiently kill a tumor at the position of the tumor, and then the aim of treating the tumor is achieved.

The invention belongs to the field of biological medicines, and particularly relates to application of exosomes derived from menstrual blood stem cells on preparation of a medicament for treating intrauterine adhesion. After primary isolation, culture and passage of the menstrual blood stem cells are carried out, 3rd-6th generations of menstrual blood stem cells are selected for exosomes preparation. When the density of the menstrual blood stem cells reaches 80%, serum components are removed by PBS washing, serum-free DMEM-F12 culture medium is added, and the menstrual blood stem cells are cultured in an incubator at the conditions of 37 DEG C, 5% CO2 and saturated humidity for 24 hours. The supernate is collected, the exosomes are prepared by ultracentrifugation under GMP conditions, andsterile PBS is collected and stored at the temperature of 80 DEG C. The cells have the advantages of being high in survival rate, stable in characters and easy to acquire and expand, and having an obvious treatment effect on intrauterine adhesion. The exosomes can even completely simulate the biological function of the cells to achieve the effects of promoting tissue repair and treating diseases.The exosomes are safer than the cells where the exosomes are derived from, do not lose functions after cryopreservation, can be used for allotransplantation and are suitable for mass production, and have important clinical application values and social and economic benefits.

The present invention relates to methods of diagnosing chronic rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, or a combination of genomic and proteomic expression profiling.

The invention discloses a compound Chinese traditional medicine preparation for inducing immune tolerance and preparing method and application thereof. The compound Chinese traditional medicine preparation comprises 2-30 parts of roots of Chinese thorowax, 3-31 parts of moutan bark, 4-32 parts of radix paeoniae alba, 5-33 parts of radix curcumae and 6-35 parts of liquorice. The above components are prepared according to the proportion, to be smashed, soaked with water, decocted, filtered, centrifuged and dried to be made into capsules, oral liquid, tablets and the like. The compound Chinese traditional medicine preparation can induce generation of DC regs of high-expression CD11b and low-expression HLA-DR/CD86/CD80, the DCregs generated through inducing can effectively inhibit DC-mediated lymphopoiesis and promote secretion of cytokines IL-10; a receptor mice is induced to tolerate the iso-allotransplantation skin; no influence on the motility rate of DC cells and the hepatorenal function of the receptor mice is generated, and the compound Chinese traditional medicine preparation is effective and low-toxic and induces immune tolerance.

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods described herein provide for injection of ISV agents into a nerve graft prior to implantation of the nerve graft into a recipient. Methods described herein also provide for injection of ISV agents with a polymerizable carrier into a nerve graft, polymerization of the carrier within the graft, and implantation of the nerve graft into a recipient. Certain embodiments provide for reinnervation of central nervous system (CNS) axons in a spinal cord utilizing a peripheral nerve graft.

Prediction of allograft rejection is provided based on the quantification of transplant-derived circulating cell-free DNA (dd-cfDNA levels) in the absence of a donor genotype. The technology provided herein alleviates some of the barriers to the implementation of Genome Transplant Dynamics (GTD), which will further widen its clinical application.

The invention relates to a method for producing a tissue matrix for an allotransplantation or a xenotransplantation, according to which, once a biological tissue has been obtained, said tissue is classified, said tissue is treated and the tissue matrix produced is conditioned, all of said steps being implemented in an automated manner inside the same 'classified' reactor. The invention also relates to the reactor allowing the implementation of the method of the invention.